The formation of autophagosomes during lysosomal defect: A new source of cytotoxicity by Button, RW & Luo, S
1 
 
The formation of autophagosomes during lysosomal defect: a new source of 
cytotoxicity 
Robert W. Button and Shouqing Luo* 
 
Peninsula Schools of Medicine and Dentistry, Institute of Translational and Stratified 
Medicine, University of Plymouth, Research Way, Plymouth PL6 8BU, UK.  
 
*Correspondence to Shouqing Luo; Email: shouqing.luo@plymouth.ac.uk 
 
Macroautophagy/autophagy comprises autophagosome synthesis and 
lysosomal degradation. It is well known that lysosomal defects cause toxicity to 
cells. However, it has not been investigated previously if cytotoxicity is 
conferred by autophagosome formation during lysosomal defect. Recently, we 
found that the formation of autophagosomes in such conditions also causes 
cytotoxicity, in addition to lysosomal defect insults. We revealed that a partial 
reduction in autophagosome synthesis was beneficial for cell survival in cells 
bearing the autophagosome formation-based toxicity. Our study suggests that 
production/accumulation of autophagosomes during lysosomal defect directly 
induces cellular toxicity, and this process may be implicated in the pathological 
conditions where lysosomes are defective.  
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The autophagy process includes autophagosome biogenesis, autophagosome-
lysosome fusion and cargo degradation. In certain stress conditions, increased 
autophagosome synthesis may be associated with decreased lysosomal activity, 
which results in reduced clearance of autophagosomes by the rate-limiting lysosomal 
activity. It is well known that lysosomal defect causes cellular toxicity, since all 
lysosome-related pathways, including autophagy, are dysfunctional in such conditions. 
However, it is unknown if autophagosome formation itself during lysosomal failure also 
causes toxicity. One can expect that the synthesis of autophagosomes in such 
conditions may yield no survival benefit, since they cannot be cleared and recycled 
when lysosomes are defective. We have now extensively demonstrated that the 
formation of autophagosomes that subsequently fail to fuse with lysosomes directly 
induces cytotoxicity. 
 
We initially observed that increased autophagosome accumulation during lysosomal 
defect occurs with cell viability loss or cell death. Therefore, we asked if 
autophagosome formation per se causes cytotoxicity under these conditions, in 
addition to the lysosomal-defect toxicity. To establish a model for autophagosome 
formation coupled with lysosomal defect, we first simultaneously employed siRNAs for 
MTOR, encoding an autophagosome synthesis repressor, and STX17, encoding a 
SNARE protein responsible for autophagosome-lysosome fusion. Treatment with 
MTOR and STX17 siRNA therefore results in autophagosome formation induction, and 
a blockade to autophagosome-lysosome fusion, respectively. Interestingly, we found 
that dual knockdown of MTOR/STX17 synergistically induces significant toxicity at a 
much higher degree than that of either of them alone. These data suggest that 
autophagosome formation during lysosomal defect can induce toxicity independent of 
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lysosomal defect insults. We replicated MTOR and STX17 dual knockdown toxicity by 
substituting STX17 for the alternative target VPS33A, a member of the HOPS complex 
that is also required for autophagosome-lysosome fusion. This approach was to 
ensure that the viability loss from our dual knockdown treatments was attributed to 
increased autophagosome formation coupled with inhibition of autophagosome-
lysosome fusion. Consistently, we observed that MTOR and VPS33A dual knockdown 
also synergistically cause cell viability loss. 
 
Because MTOR ablation may affect additional cellular pathways other than 
autophagosome synthesis, we also attempted to target an MTOR-independent 
pathway to exclude any potential cytotoxicity effects from other pathways in our MTOR 
and STX17 or MTOR and VPS33A dual knockdown assays. Studies have shown that 
reductions in free inositol lead to enhanced autophagosome synthesis, independently 
of MTOR pathways. As such, using siRNAs we targeted IMPA1 (inositol [myo]-1[or 4]-
monophosphatase 1), an MTOR-independent autophagy regulator, along with 
SNAP29 (which is important for autophagosome-lysosome fusion) to mimic the role of 
MTOR and STX17 for cytotoxicity induction. Consistently, while knockdown of either 
IMPA1 or SNAP29 alone leads to a modest reduction in cell viability, IMPA1 and 
SNAP29 dual knockdown dramatically enhance cytotoxicity. Importantly, we showed 
that the cytotoxicity from MTOR and STX17 or IMPA1 and SNAP29 dual knockdown 
is alleviated when autophagosome formation is specifically inhibited by ATG gene 
knockdown. Chemical treatments were also used to consolidate the data from genetic 
approaches. Treatment with the dual PI3K and MTOR inhibitor PI-103 induces both 
autophagosome accumulation and cell death. Interestingly, whereas the lysosome 
inhibitor bafilomycin A1 exacerbates the cell death caused by PI-103, blocking 
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autophagosome formation with 3-methyladenine provides significant protection from 
PI-103 lethality. Together, these data indicate that the formation of autophagosomes 
that subsequently fail to fuse with lysosomes (during lysosomal defect) confers 
cytotoxicity. 
 
We found the toxicity to occur independently of the 2 major cell death routes, apoptosis 
and necroptosis, because chemical and genetic inhibition of either pathway fails to 
afford any cytoprotective effects. We sought to reveal the sources of toxicity, and found 
that an increase in reactive oxygen species (ROS) production and intracellular energy 
deficit at least in part contribute to the toxicity. As lysosome defects mean that 
autophagosomes and their contents cannot be degraded and recycled, continued 
autophagosome synthesis only serves to deplete cellular energy and nutrition levels, 
as well as generate increased ROS, thereby resulting in toxicity. Because the 
continued formation of autophagosomes during lysosomal failure (or autophagosome 
accumulation) confers the cytotoxicity, we designated it as autophagosome 
accumulation toxicity. 
 
Autophagosome accumulation toxicity could have implications in many disease 
conditions. We have shown that partially reducing the formation of autophagosomes 
alleviates the toxicity from mutant HTT (huntingtin) and SNCA (synuclein, alpha). 
Strategies of inducing autophagosome accumulation toxicity could represent a novel 
approach in future tumor treatments. A number of pathological conditions are 
associated with lysosomal defects, such as neurodegenerative disorders featuring 
toxic protein aggregates, and lysosomal-storage diseases. Therefore, 
autophagosome accumulation toxicity may be of particular interest and relevance to 
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studies into these diseases. Currently, inducing autophagy via stimulating 
autophagosome formation has been adopted as a frequently used strategy to attempt 
to treat these diseases. Our study argues that such a strategy of inducing 
autophagosome formation during periods of lysosomal defect will not be beneficial, 
but in fact detrimental to cells.  
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